Show simple item record

dc.contributor.authorEspinosa, Marta
dc.contributor.authorRoldán-Romero, Juan Maria
dc.contributor.authorDuran, Ignacio
dc.contributor.authorde Álava, Enrique
dc.contributor.authorApellaniz-Ruiz, María
dc.contributor.authorCascon Soriano, Alberto 
dc.contributor.authorGarrigos, Carmen
dc.contributor.authorRobledo Batanero, Mercedes 
dc.contributor.authorRodriguez Antona, Cristina 
dc.date.accessioned2018-11-21T12:07:25Z
dc.date.available2018-11-21T12:07:25Z
dc.date.issued2018-05-15
dc.identifier.citationBreast Cancer Res. 2018;18(1):561.es_ES
dc.identifier.issn1471-2407es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6655
dc.description.abstractBACKGROUND: Renal epithelioid angiomyolipomas (EAML) are rare tumors with aggressive behavior. EAML can be sporadic or develop within the tuberous sclerosis complex syndrome, where mutations of TSC1 or TSC2 genes (critical negative regulators of mTOR Complex 1) result in an increased activation of mTOR pathway. Optimal EAML treatment, including mTOR inhibitors, remains undetermined. CASE PRESENTATION: Here we present the case of a young adult with a renal EAML that after radical nephrectomy developed metastases, first in liver and then in lumbar vertebrae. After complete surgical resection of these lesions, liver recurrence was detected, this time with incomplete surgical resection. After finding a new liver lesion, systemic treatment with sirolimus started. The patient exhibited a complete and durable response to this drug, being disease free at the time of publication, after 36 months of treatment. Targeted next generation sequencing (NGS) of MTOR, TSC1 and TSC2 genes in the primary tumor, metastasis and blood of the patient, revealed one inactivating TSC2 mutation (c.2739dup; p.K914*) in the tumor cells. Immunohistochemistry revealed decreased TSC2 protein content and increased phospho-S6 in the tumor cells, demonstrating mTOR pathway activation. CONCLUSION: NGS on an EAML patient with an extraordinary response to sirolimus uncovered TSC2 inactivation as the mechanism for the response. This study supports NGS as a useful tool to identify patients sensitive to mTOR inhibitors and supports the treatment of malignant EAML with these drugs.es_ES
dc.description.sponsorshipWe thank Rocío Letón and Rafael Torres for their support in the generation of NGS libraries and analysis of the data.es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectRenal epithelioid angiomyolipomaes_ES
dc.subjectSirolimuses_ES
dc.subjectTSC2 mutationes_ES
dc.subjectmTOR pathway activationes_ES
dc.titleAdvanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutationes_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29764404es_ES
dc.format.volume18es_ES
dc.format.number1es_ES
dc.format.page561es_ES
dc.identifier.doi10.1186/s12885-018-4467-6es_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)
dc.contributor.funderMinisterio de Economia y Competitividad (España)
dc.description.peerreviewedes_ES
dc.identifier.e-issn1471-2407es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s12885-018-4467-6.es_ES
dc.identifier.journalBMC canceres_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Cáncer Endocrino Hereditarioes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2015-70820-ERCes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2015-64850-Res_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional